Results 81 to 90 of about 2,303 (187)

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods A cohort model was ...
Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W. Law, Diana Mendes   +9 more
doaj   +1 more source

Nirsevimab som skydd mot Respiratorisk syncytialvirus (RSV) hos spädbarn : Hur effektivt och säkert är nirsevimab som skydd mot RSV hos friska spädbarn?

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among children and represents a major global health concern. Most RSV cases occur during the RSV season, which is during the cold seasons of the year. The infection often begins as
Awad, Zainab
core   +2 more sources

Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants

Importance: Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations, and preterm infants and those with older siblings are at increased risk.
Lorefice, Aurora, Accomando, Francesco, Valletta, Enrico, Morlupo, Francesco Saverio, Pellegrini, Benedetta, Stella, Marcello, Cocchi, Enrico, Scarpellini, Beatrice, Aricò, Melodie O., Aric\uf2, Melodie O., Vergine, Gianluca, Zannoni, Sara, Bloise, Silvia, Ancora, Gina, Marchetti, Federico   +14 more
core   +1 more source

Nirsevimab (▼Beyfortus®): un nuevo anticuerpo monoclonal para la profilaxis frente al virus respiratorio sincitial [PDF]

, 2023
Farmacologia; Medicaments; Virus respiratori sincicialFarmacología; Medicamentos; Virus respiratorio sincicialPharmacology; Medicines; Respiratory syncytial virusAquest article tracta del medicament nirsevimab, un nou anticòs monoclonal que actua ...

core  

Reluctance of parents to immunize their children with nirsevimab

Anales de Pediatría (English Edition)
2025
Piñeiro Pérez, Roi, Galán Arévalo, Sonsoles, Risso, Milagros, Hidalgo Montes, Inmaculada, López Escobar, Alejandro   +4 more
openaire   +3 more sources

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months

Children
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, Doina Anca Pleșca   +4 more
doaj   +1 more source

Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +1 more source

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

The Journal of Clinical Pharmacology
AbstractNirsevimab, a monoclonal antibody with an extended half‐life, is approved for the prevention of respiratory syncytial virus (RSV) disease in all infants in Canada, the EU, Great Britain, and the USA. A population pharmacokinetics (PK) model was built to describe the PK of nirsevimab in preterm and term infants, and to evaluate the influence of ...
Lindsay Clegg, Ed Freshwater, Amanda Leach, Tonya Villafana, Ulrika Wählby Hamrén   +4 more
openaire   +2 more sources

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available.
Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin   +9 more
doaj   +1 more source